Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical device maker Vascular Solutions (Nasdaq: VASC) earned a respected four-star ranking.

With that in mind, let's take a closer look at Vascular's business and see what CAPS investors are saying about the stock right now.

Vascular facts

Headquarters (Founded)

Minneapolis, Minn. (1996)

Market Cap

$192.1 million

Industry

Health-care supplies

Trailing-12-Month Revenue

$73.16 million

Management

Co-Founder/CEO Howard Root
CFO James Hennen

Return on Capital (Average, Past 3 Years)

15.9%

Cash/Debt

$18.23 million / $0

Competitors

Abbott Labs (NYSE: ABT)
Medtronic (NYSE: MDT)
Boston Scientific (NYSE: BSX)
Johnson & Johnson (NYSE: JNJ)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 89% of the 84 members who have rated Vascular believe the stock will outperform the S&P 500 going forward. These bulls include strovek and AlphaCenturion.

Three months ago, strovek brought Vascular's solid fundamentals to our community's attention: "The company has no debt and the margin is consistent. Asset growth is consistent and cash flow is positive."

As a micro-cap medical device company focused on coronary and vascular procedures, Vascular Solutions is one of the more obscure ways to play the aging boomer demographic. While the space is dominated by large, deep-pocketed players like Medtronic, Abbott, and Boston Scientific, Vascular has managed to post double-digit revenue growth and returns on capital over the past three years. And with Johnson & Johnson recently gobbling up a similar stroke-preventing small fry, Micrus Endovascular, Vascular Solutions might even be a tasty takeover target for one of those medical-device giants.

CAPS member AlphaCenturion sums up the bull case:

The rapid growth in vascular medicine shouldn't be surprising given the declining health of your average American over the last several years. I don't imagine this growth will slow any time soon and unlike your less invasive vascular treatments, medical devices aren't subject to threats from generic competition. ... As per usual, I'll be tracking this on CAPS for now and if the opportunity presents itself I may consider starting a position. The potential here is enormous.

What do you think about Vascular, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Johnson & Johnson is a Motley Fool Income Investor pick, and Motley Fool Options has recommended a diagonal call position on it. The Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days.

True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community. The Fool's disclosure policy always gets a perfect score.